In the TARGET-AML dataset, on the other hand, we found significant upregulation for TCF3, RUNX1T1, PALM, SHANK1, CSNK2A1, TPPP3, SLCO5A1, M1AP, and LINC00189 in RUNX1/RUNX1T1-positive patients; whereas, KLF4, ADCY7, TSPAN32, ADARB1, PPARD, HDX, and ESR1 were significantly downregulated in them compared to RUNX1/RUNX1T1 = negative patients (Figure 7b). This evidence concerns the gene RUNX1 and acute myeloid leukemia.